XP Inc. (XP)

CTI BioPharma Income Statement

Financials in millions BRL. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Interest Expense	775.38	779.53	617.48	402.3	135.73	52.67
Net Interest Income	-775.38	-779.53	-617.48	-402.3	-135.73	-52.67
Brokerage Commission	3,140	3,130	2,782	2,667	2,658	2,231
Asset Management Fee	1,746	1,743	1,628	1,581	1,490	1,224
Gain on Sale of Investments (Rev)	2,273	2,285	1,979	1,631	1,917	1,430
Other Revenue	10,164	9,873	8,471	7,468	6,012	3,267
Revenue	16,547	16,251	14,243	12,945	11,941	8,099
Revenue Growth (YoY)	9.27%	14.10%	10.02%	8.40%	47.44%	60.59%
Cost of Services Provided	11,229	11,122	9,964	9,580	8,297	5,750
Other Operating Expenses	-162.97	-145.59	-23.48	-214.92	-278.8	-224.4
Total Operating Expenses	11,404	11,265	10,301	9,459	8,110	5,581
Operating Income	5,143	4,987	3,941	3,486	3,831	2,518
EBT Excluding Unusual Items	5,191	5,034	4,015	3,474	3,823	2,519
Asset Writedown	-19.15	-29.45	-32.27	-20.81	-20.37	-73.14
Legal Settlements	-11.4	-18.55	-46.1	-8.56	-3.67	-45.28
Pretax Income	5,160	4,986	3,936	3,445	3,815	2,421
Income Tax Expense	438.89	471.13	36.96	-135.56	222.71	339.92
Earnings From Continuing Ops.	4,721	4,515	3,899	3,580	3,592	2,081
Minority Interest in Earnings	-2.44	-1.43	-0.69	-1.16	-3.04	-5.06
Net Income	4,719	4,513	3,899	3,579	3,589	2,076
Net Income to Common	4,719	4,513	3,899	3,579	3,589	2,076
Net Income Growth	14.16%	15.77%	8.93%	-0.29%	72.87%	92.18%
Shares Outstanding (Basic)	538	542	540	555	559	552
Shares Outstanding (Diluted)	544	548	544	573	573	559
Shares Change (YoY)	-0.93%	0.76%	-5.03%	-0.09%	2.57%	9.26%
EPS (Basic)	8.76	8.33	7.22	6.44	6.42	3.76
EPS (Diluted)	8.67	8.23	7.16	6.25	6.26	3.71
EPS Growth	15.23%	14.90%	14.69%	-0.20%	68.53%	75.88%
Free Cash Flow	11,759	11,034	8,061	1,759	-4,156	1,366
Free Cash Flow Per Share	21.61	20.12	14.81	3.07	-7.25	2.44
Dividend Per Share	-	-	6.357	-	-	-
Operating Margin	31.08%	30.69%	27.67%	26.93%	32.08%	31.09%
Profit Margin	28.52%	27.77%	27.37%	27.65%	30.06%	25.64%
Free Cash Flow Margin	71.07%	67.90%	56.60%	13.59%	-34.80%	16.86%
Effective Tax Rate	8.51%	9.45%	0.94%	-	5.84%	14.04%
Revenue as Reported	17,323	17,031	14,860	13,347	12,077	8,152

Updated Feb 19, 2025. Source: S&P Global Market Intelligence. Capital Markets template. Financial Sources.

SEC Filings: 10-K · 10-Q